Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last ¥8,030 JPY
Change Today +58.00 / 0.73%
Volume 1.1M
4523 On Other Exchanges
As of 2:00 AM 06/2/15 All times are local (Market data is delayed by at least 15 minutes).

eisai co ltd (4523) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/24/15 - ¥9,756
52 Week Low
06/13/14 - ¥4,064
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for EISAI CO LTD (4523)

Related News

No related news articles were found.

eisai co ltd (4523) Related Businessweek News

No Related Businessweek News Found

eisai co ltd (4523) Details

Eisai Co., Ltd. manufactures and sells pharmaceutical products worldwide. The company offers oncology-related products, such as Halaven, an anticancer agent; Aloxi, an antiemetic agent; and Fragmin, an injectable anticlotting agent, as well as Symbenda/Treakisym, a treatment for low-grade non-Hodgkin's lymphoma and other types of lymphatic cancer. It also provides Aricept, an anti-Alzheimer's agent; Pariet/AcipHex, a proton-pump inhibitor; and Humira, a human anti-TNF-a monoclonal antibody. In addition, the company offers epilepsy products comprising Zonegran, Zebinix, and Fycompa, which are antiepileptic agents; and Inovelon/BANZEL for the treatment of Lennox-Gastaut syndrome, as well as consumer healthcare (over-the-counter) products, which include vitamin B2 preparation Chocola BB Plus. Further, it provides Methycobal, a peripheral neuropathy treatment; Warfarin, an oral anticoagulant; Actonel, an osteoporosis treatment; Selbex for the treatment of gastritis/gastric ulcer; BELVIQ, an antiobesity agent; Stronger Neo-Minophagen C/Glycyron tablets for liver disease/allergic disease treatment; Lyrica, a treatment for postherpetic neuralgia; and Lunesta, a treatment for insomnia. Additionally, the company is involved in the research and development of various products under the areas of oncology, vascular and immunological reaction, gastrointestinal and hepatic disorders, and neurology. It has strategic partnerships with Quintiles Inc.; SFJ Pharma Ltd.; Biogen Idec, Inc.; BioArctic Neuroscience AB; FORMA Therapeutics, Inc.; Epizyme, Inc.; PRISM BioLab Co., Ltd.; and Verastem, Inc. for the discovery and development of various products. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was founded in 1941 and is headquartered in Tokyo, Japan.

10,183 Employees
Last Reported Date: 05/14/15
Founded in 1941

eisai co ltd (4523) Top Compensated Officers

Chief Executive Officer, Representative Corpo...
Total Annual Compensation: ¥115.0M
Chief Clinical Officer of Eisai Product Creat...
Total Annual Compensation: ¥84.0M
Compensation as of Fiscal Year 2014.

eisai co ltd (4523) Key Developments

Eisai Announces Fycompa® (Perampanel) Receives Positive CHMP Opinion for Primary Generalised Tonic-Clonic Seizures

Eisai Co., Ltd. announced that Fycompa® (perampanel) received positive opinion for use as a once-daily, adjunctive therapy for primary generalised tonic-clonic seizures in adult and adolescent patients from 12 years of age with idiopathic generalised epilepsy from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP). In the first randomised, Phase III, double-blind, placebo-controlled trial to evaluate the efficacy and safety of adjunctive perampanel for the treatment of primary generalised tonic-clonic (PGTC) seizures in patients aged =12 years with idiopathic generalised epilepsy, 164 patients were randomised and included 81 patients who received perampanel and 81 patients who received placebo. Results show that reduction in PGTC seizure frequency was greater in patients receiving perampanel compared with placebo (76.5% versus 38.4%, respectively; P<0.0001). The 50% responder rate for patients with PGTC seizures was also greater with perampanel than placebo (64.2% versus 39.5%, respectively; P=0.0019. Both of these are primary endpoints. Furthermore, 31% of patients were seizure free during the 13-week maintenance period when treated with perampanel as an adjunctive therapy, compared to 12% in the placebo group. Patients treated with perampanel also experienced improved quality of life across all domains measured, including daily activities, cognition and distress. Perampanel is currently indicated for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older. Perampanel is the only licensed anti-epileptic drug (AED) to selectively target AMPA receptors, a protein in the brain which plays a critical role in the spread of seizures. This mechanism of action is different to other, currently available AEDs. In addition, perampanel has the added benefit of convenient, once-daily dosing at bed time. Generalised tonic-clonic seizures can be a dangerous type of epilepsy. The seizures start with a loss of consciousness and a sudden contraction of the muscles, which can cause the person to fall down (tonic phase). This is followed by violent convulsions (clonic phase) until the muscles finally relax. Between 20%-40% of people with newly diagnosed epilepsy are, or become refractory to treatment, resulting in a potential negative impact on quality of life. Perampanel was investigated in PGTC in study 332, a double-blind, randomised, placebo-controlled, multicentre, parallel-group trial to evaluate the efficacy and safety of adjunctive perampanel for refractory tonic-clonic seizures in patients with idiopathic generalised epilepsy. Results demonstrate that perampanel significantly reduces the number of PGTC seizures, the study's primary outcome measure, when compared to placebo. Perampanel was generally well tolerated, the most frequent adverse events (10% in the perampanel arm and greater than placebo) were dizziness, fatigue and headache, irritability and somnolence. The adverse event profile in this study is similar to that for other perampanel studies.

Eisai Co., Ltd. Launches In-House Developed Novel Anticancer Agent Lenvima (Lenvatinib Mesylate) as Treatment for Unresectable Thyroid Cancer in Japan

Eisai Co., Ltd. announced that it has launched its in-house developed novel anticancer agent Lenvima Capsule 4 mg and 10 mg (lenvatinib mesylate, 'Lenvima') as a treatment for unresectable thyroid cancer in Japan on May 20, 2015. Lenvima is the first molecular targeted treatment in Japan approved with an indication for unresectable thyroid cancer which covers differentiated thyroid cancer as well as medullary thyroid carcinoma and anaplastic thyroid carcinoma. In a global Phase III study (the SELECT study) of Lenvima in differentiated thyroid cancer, Lenvima demonstrated a statistically significant extension in progression free survival and improved response rates compared to placebo. In the SELECT study, the five most common Lenvima treatment-related adverse events of any grade were hypertension, diarrhea, fatigue or asthenia, decreased appetite, and weight loss. Furthermore, a Phase II study (Study 208) conducted in Japan suggested tolerability and efficacy of Lenvima in medullary thyroid carcinoma and anaplastic thyroid carcinoma as well. The number of patients with thyroid cancer in Japan is estimated to be between 13,000 and 29,000. Although treatment is possible for most types of thyroid cancer, there are few treatment options available for unresectable thyroid cancer and so there is a pressing need for the development of new treatment options. With a high degree of clinical malignancy and a prognosis among the worst of all types of cancer, anaplastic thyroid carcinoma in particular is a disease with significant unmet medical needs. Eisai hopes that Lenvima will make a contribution to patients as a new standard treatment for unresectable thyroid cancer, which has no established standard treatment in Japan at present. Discovered at Eisai's Tsukuba Research Laboratories and developed in-house, Lenvima is an orally administered molecular targeted agent that selectively inhibits the activities of several different molecules including VEGFR, FGFR, RET, KIT and PDGFR. In particular, the agent simultaneously inhibits VEGFR, FGFR and also RET which are especially involved in tumor angiogenesis and proliferation of thyroid cancer. Furthermore, Lenvima has been confirmed through X-ray co-crystal structural analysis to demonstrate a new binding mode (Type V) to VEGFR2, and exhibits rapid binding to the target molecule and potent inhibition of kinase activity, according to kinetic analysis.

Eisai Co., Ltd. Reports Consolidated and Non-Consolidated Earnings Results for the Year Ended March 31, 2015; Provides Earnings Guidance for the Six Months Ending September 30, 2015 and for the Year Ending March 31, 2016; Announces Year End Dividend for the Fiscal Year Ended March 31, 2015, Payable on May 22, 2015; Provides Interim and Year End Dividend Guidance for the Fiscal Year Ending March 31, 2016

Eisai Co., Ltd. reported consolidated and non-consolidated earnings results for the year ended March 31, 2015. For the year on consolidated basis, the company reported revenue of JPY 548,465 million against JPY 599,490 million a year ago. Operating profit was JPY 28,338 million against JPY 66,398 million a year ago. Profit before income taxes was JPY 25,875 million against JPY 62,298 million a year ago. Profit for the year was JPY 43,453 million against JPY 38,501 million a year ago. Attributable to owners of the parent was JPY 43,254 million against JPY 38,251 million a year ago. Diluted earnings per share were JPY 151.37 against JPY 134.01 a year ago. Net cash from operating activities was JPY 76,022 million against JPY 91,276 million a year ago. Purchases of property, plant and equipment was JPY 11,483 million against JPY 8,570 million a year ago. Purchases of intangible assets were JPY 6,942 million against JPY 18,814 million a year ago. For the year on non-consolidated basis, the company reported revenue of JPY 311,160 million against JPY 342,069 million a year ago. Operating profit was JPY 18,756 million against JPY 36,386 million a year ago. Profit before income taxes was JPY 15,136 million against JPY 31,998 million a year ago. Profit for the year was JPY 21,128 million against JPY 12,562 million a year ago. Diluted earnings per share were JPY 73.94 against JPY 44.01 a year ago. For the six months ending September 30, 2015, the company expects revenue of JPY 277,500 million, operating profit of JPY 10,000 million, profit before income taxes of JPY 8,400 million, profit for the year of JPY 6,000 million, basic earnings per share attributable to owners of the parent of JPY 20.66. For the year ending March 31, 2016, the company expects revenue of JPY 556,500 million, operating profit of JPY 46,000 million, profit before income taxes of JPY 42,800 million, profit for the year of JPY 42,800 million, basic earnings per share attributable to owners of the parent of JPY 93.83. The company announced year end dividend of JPY 80.00 per share for the fiscal year ended March 31, 2015, same as previous year. Expected date of dividend payment commencement is May 22, 2015. The company provided interim and year end dividend guidance for the fiscal year ending March 31, 2016. The company expects to pay interim dividend of JPY 70.00 per share same as previous year. The company expects to pay year end dividend of JPY 80.00 per share same as previous year.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4523:JP ¥8,030.00 JPY +58.00

4523 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Almirall SA €18.77 EUR 0.00
Ironwood Pharmaceuticals Inc $13.76 USD +0.12
Nektar Therapeutics $11.78 USD +0.30
Synergy Health PLC 1,820 GBp +7.00
Theravance Inc $16.68 USD -0.265
View Industry Companies

Industry Analysis


Industry Average

Valuation 4523 Industry Range
Price/Earnings 51.0x
Price/Sales 4.0x
Price/Book 3.7x
Price/Cash Flow 52.9x
TEV/Sales 3.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EISAI CO LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at